Treatment of Seizures and Prevention of Long-Term Epilepsy
Inventors: Frances Jensen, Sanjay Rakhade, Chengwen Zhou
Invention Types: Therapeutics
Research Areas: Neonatology/Pediatric, Neurology/Neuroscience
Keywords: Animal Model (rat), Disease Model, Method of Use, Small Molecule/DrugFor More Information Contact: Caron, Connie
Investigators at Children's Hospital Boston have discovered a cascade of molecular events that are triggered by seizures, thereby uncovering targets for therapeutics that could be targeted drugs. Results show that use of AMPA receptor antagonists can block the processes of epileptogenesis.
The Jensen laboratory's sophisticated rat model for inducing and studying the downstream effects of seizures and the epileptogenesis processes can be used to identify new targets and pathways that could be promising in the treatment of epilepsy and also autism, which, for many patients, is associated with seizures.
The targets and therapeutics described in this invention represent novel pathways in the treatment and prevention of long-term epilepsy. The described invention represents a new treatment modality for epilepsy, with the possibility of developing a first-in-class therapeutic compound.
There are many drugs on the market that address epilepsy, though not all work equally well for all patients. The discovery of new pathways associated with the development of long-term epilepsy and autism opens up the potential for developing new therapeutics and to use these to address seizure disorders earlier and also as adjuncts to the existing therapies.
Exclusive License|Sponsored research|Collaboration
Key Publications: Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.
|Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, Jensen FE.
|J Neurosci. 2008 Aug 6;28(32):7979-90.
IPStatus: Pat. Pend.